Skip to content

FIGHTING OVERWEIGHT AND OBESITY

Empros Pharma develops EMP16, a pharmaceutical weight management treatment. The EMP16 product has demonstrated its efficacy in a proof-of-concept clinical trial. The early phase safety and tolerability trials are finalized, demonstrating a best-in-class safety profile.

Read more

PRESS RELEASE

EMPROS PHASE 2B OBESITY TRIAL ENROLLMENT COMPLETE IN ONLY ONE MONTH

In just one month, 320 patients have successfully been randomized in the phase 2b SESAM trial. This confirms the unmet medical need for safe and effective oral anti-obesity drugs. The completion of the SESAM trial by Q1 2024 is now secured which will enable the remaining phase 3 trials to start during 2024 and deliver data in 2025.

Read more

Blog

A SHORT OVERVIEW OF THE CHRONIC DISEASE OBESITY

Obesity is a complex and chronic medical condition characterized by the excessive accumulation of body fat to a degree that adversely affects an individual's health. Obesity is a multifaceted issue, involving genetic, environmental, behavioral, and socio-economic factors. Here we give an overview of this complex disease.

Read more

EMP16 – A NEW APPROACH TO FIGHTING OBESITY

Empros Pharma has developed a revolutionary oral drug – EMP16. The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 thereby support and increase the natural endogenous satiety response present in the gastrointestinal system to regulate food intake. An important distinction to other, often hormone-based satiety regulating pharmaceuticals (that will act on one or a few of the hormone signaling pathways) is that EMP16 enhances the entire endogenous hormone response in a physiological way. Based on the clinical trials, EMP16 is a safe and efficient method to address the medical need of patients with obesity.

Read more